Skip to content

Blog

Pfizer Q3 2026: $16.6B Revenue, Guidance Raised and New CFO

Pfizer reported $16.6 billion in Q3 revenue, raised full-year guidance for revenue and adjusted EPS, took a $650M one-time R&D charge, and named Cecile Guegan as CFO.

Vero AIUpdated November 5, 20261 min read
AI-generated, reviewed against cited sources

Published by Vero, the Intelligence Operating System for investors: news scored for importance, thesis tracking and an AI investing copilot, for long-term investors and active traders.

white ceramic sink with stainless steel faucet Laboratory. Tube (vial) with body material being transported on a track to analyzer in large Dutch lab.
white ceramic sink with stainless steel faucet Laboratory. Tube (vial) with body material being transported on a track to analyzer in large Dutch lab.Photo by Testalize.me(opens in a new tab) on Unsplash(opens in a new tab)

Pfizer reported third-quarter 2026 results and raised its full-year guidance, according to its filings with the SEC.

Quarterly results and guidance

For the quarter ended September 27, 2026, Pfizer reported revenue of $16.6 billion and said it has raised its full-year guidance for both revenue and adjusted EPS. Adjusted EPS refers to earnings per share that the company reports after excluding certain one-time items.

The company said non-COVID products grew during the quarter, and that launched and acquired products rose 32% on an operating basis.

One-time R&D charge and EPS impact

Pfizer recorded a one-time Acquired In-Process R&D (research and development) charge of $650 million in the quarter. The filing states that this charge reduced the quarter's reported EPS by about $0.10.

CFO appointment

Pfizer disclosed that Cecile Guegan was elected Chief Financial Officer and Executive Vice President, effective November 1, 2026. The company said she had been serving as interim CFO since August 16, 2026.

The SEC filing outlines her compensation: a $1.3 million base salary and a $1.3 million target cash incentive.

Regulatory filing

In connection with the quarter, Pfizer also filed its Form 10-Q for the period ended September 27, 2026. The 10-Q is described in the filing as a routine regulatory update summarizing the company's results and financial condition.

The details above are drawn from Pfizer's SEC filings, which report the company's revenue, charge, guidance change and executive appointment.

#PFE#earnings#cfo#guidance

Sources

This article was written from the reporting below. Every claim should be checkable against one of these. Entries without a link are cited by outlet and date so you can look them up.

Vero reads the news on your stocks.

Add the tickers you own. Every headline gets an importance score and a plain-English summary of what changed.

Cookies and tracking

Vero always uses essential storage to keep you signed in. With your OK, it also uses Google Analytics to see how the site is used. Nothing else runs until you choose. Privacy · Cookies